<DOC>
	<DOCNO>NCT01436175</DOCNO>
	<brief_summary>This study optional continuation previous short-term adult major depressive disorder ( MDD ) augmentation study . Patients may take part long-term , open-label research study complete previous double-blind MDD augmentation study use SPD489 .</brief_summary>
	<brief_title>SPD489 Adult Major Depressive Disorder ( MDD ) Open-label Safety Tolerability Rollover Extension Study</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Subject complete 1 respective shortterm antecedent SPD489 MDD study experience clinically significant AEs antecedent study would preclude exposure SPD489 . Subject current comorbid Axis I Axis II psychiatric disorder ( include lifetime history psychosis ) present recognize entry antecedent study concurrent chronic acute illness unstable medical condition may deteriorate could confound result safety assessment , increase risk subject lead difficulty comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>